Shuttle Pharmaceuticals Holdings (SHPH) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Sep 24, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SHPH SEC filings page.
This page shows Shuttle Pharmaceuticals Holdings, Inc. (SHPH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business is still funding expanding operating losses externally while its short-term balance-sheet cushion has sharply narrowed.
From FY2024 to FY2025, liabilities rose357.5% while current assets fell77.3% , shifting the financing structure toward obligations due soon. The current ratio fell from 1.4x to 0.1x, showing that the balance-sheet expansion did not translate into readily available working capital.
Operating losses widened from
FY2025 operating cash flow was
Financial Health Signals
Shuttle Pharmaceuticals Holdings, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Shuttle Pharmaceuticals Holdings, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Shuttle Pharmaceuticals Holdings, Inc. reported a net loss of $11.7M while operations used $9.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Shuttle Pharmaceuticals Holdings, Inc.'s EBITDA was -$3.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Shuttle Pharmaceuticals Holdings, Inc. reported a net loss of $3.1M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Shuttle Pharmaceuticals Holdings, Inc. earned -$3.10 per diluted share (EPS) in Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Shuttle Pharmaceuticals Holdings, Inc. held $90K in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Shuttle Pharmaceuticals Holdings, Inc.'s quarterly ROE was -16.4% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is up 86.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 47.9 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Shuttle Pharmaceuticals Holdings, Inc. invested $56K in research and development in Q2 2026. This represents a decrease of 94.6% from the same quarter a year earlier. Against the prior quarter it is down 79.2%.
Not reported for Q2 2026.
Not reported for Q2 2026.
SHPH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $56K-94.6% | $267K-83.0% | N/A | $943K-32.6% | $1.0M+58.8% | $1.6M+168.5% | N/A | $1.4M+34.0% |
| SG&A Expenses | $2.0M-15.4% | $1.2M+94.4% | N/A | $886K+169.3% | $2.3M+656.8% | $597K+83.9% | N/A | $329K+23.9% |
| Operating Income | -$3.9Mn/m | -$2.2Mn/m | N/A | -$2.3Mn/m | -$3.9Mn/m | -$3.0Mn/m | N/A | -$3.1Mn/m |
| EBITDA | -$3.3Mn/m | -$1.6Mn/m | N/A | N/A | -$3.9Mn/m | -$3.0Mn/m | N/A | -$3.1Mn/m |
| Net Income | -$3.1Mn/m | -$2.2Mn/m | N/A | -$2.3M | -$3.7Mn/m | -$3.1Mn/m | N/A | N/A |
| EPS (Basic) | -$3.10 | -$0.43 | $0.06-76.9% | -$1.05 | -$32.91 | -$7.60 | $0.26 | -$39.83 |
| EPS (Diluted) | -$3.10 | -$0.43 | $0.06-60.0% | -$1.05 | -$32.91 | -$7.60 | $0.15 | -$39.83 |
| Diluted Shares (Avg) | 1M | 5M | N/A | 2M | 112,611 | 401,957 | N/A | 95,004 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
SHPH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $22.8M+314.4% | $11.8M+122.4% | $10.5M+318.0% | $3.5M+426.0% | $5.5M+95.7% | $5.3M+11.7% | $2.5M-57.9% | $674K-90.9% |
| Current Assets | $396K-92.4% | $2.5M-50.3% | $503K-77.3% | $3.3M+803.8% | $5.2M+108.9% | $5.0M+12.4% | $2.2M-60.5% | $361K-94.8% |
| Cash & Equivalents | $90K-98.1% | $1.1M-75.8% | $334K-82.6% | $2.1M+1237.1% | $4.8M+592.6% | $4.5M+222.6% | $1.9M-25.5% | $157K-96.0% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $3.6M+91.1% | $8.5M+317.9% | $8.2M+357.5% | $2.1M+8.0% | $1.9M-5.6% | $2.0M+1.6% | $1.8M-5.2% | $2.0M+12.6% |
| Current Liabilities | $3.5M+105.6% | $8.3M+366.0% | $8.0M+419.4% | $2.0M+18.4% | $1.7M+22.3% | $1.8M+19.7% | $1.5M+47.2% | $1.7M+104.7% |
| Non-Current Liabilities | $148K-28.2% | $157K-35.1% | $255K-3.3% | $184K-44.2% | $206K-67.1% | $243K-51.8% | $263K-69.2% | $330K-65.5% |
| Total Equity | $19.2M+432.0% | $3.3M+1.9% | $2.3M+217.9% | $1.4Mn/m | $3.6M+349.9% | $3.3M+19.0% | $709K-82.5% | -$1.3M-123.4% |
| Retained Earnings | -$51.6Mn/m | -$48.5Mn/m | -$46.3Mn/m | -$43.7Mn/m | -$41.3Mn/m | -$37.6Mn/m | -$34.6Mn/m | -$33.0Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
SHPH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$568Kn/m | -$2.4Mn/m | -$973Kn/m | -$2.6Mn/m | -$3.4Mn/m | -$2.5Mn/m | -$2.7Mn/m | -$2.0Mn/m |
| Depreciation & Amortization | $633Kn/m | $633K+62731.3% | N/A | N/A | -$979-201.8% | $1K-47.3% | N/A | $793-57.3% |
| Stock-Based Compensation | -$8K-116.0% | $35K-93.5% | N/A | $134K+196.7% | $47K-34.2% | $537K+381.9% | N/A | $45K |
| Investing Cash Flow | -$5.4M | -$36K | N/A | N/A | N/A | N/A | $0-100.0% | $1.7Mn/m |
| Financing Cash Flow | $5.0M+36.6% | $3.2M-37.3% | $2.3M-49.1% | -$96Kn/m | $3.7Mn/m | $5.1Mn/m | $4.5Mn/m | -$197Kn/m |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
SHPH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -16.4%+86.4pp | -64.3%+28.6pp | N/A | -168.4% | -102.8%+150.7pp | -92.9%-30.3pp | N/A | N/A |
| Return on Assets | -13.8%+53.5pp | -18.2%+39.3pp | N/A | -66.3% | -67.3%+4.9pp | -57.5%-21.1pp | N/A | N/A |
| Current Ratio | 0.11-3.0x | 0.30-2.5x | 0.06-1.4x | 1.66+1.4x | 3.07+1.3x | 2.78-0.2x | 1.44-3.9x | 0.22-8.4x |
| Liabilities-to-Equity | 0.19-0.3x | 2.53+1.9x | 3.65+1.1x | 1.54 | 0.53-2.0x | 0.62-0.1x | 2.53+2.1x | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: The current ratio is below 1.0 (0.06), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Shuttle Pharmaceuticals Holdings, Inc. SHPH | FY2025 | N/A | -$11.7M | N/A | $24.0M | — |
| InMed Pharmaceuticals Inc. INM | FY2026 | N/A | -$12.6M | N/A | $7.9M | — |
| Redhill Biopharma Ltd. RDHL | FY2025 | $286K | -$429K | N/A | $3.8M | — |
| PRF Technologies Ltd. PRFX | FY2025 | $17K | -$5.0M | N/A | $2.6M | — |
| Sunshine Biopharma Inc. SBFM | FY2025 | $36.3M | -$6.0M | -16.5% | N/A | 60/100 |
| Universe Pharmaceuticals Inc. UPC | FY2025 | $17.9M | -$3.7M | -20.6% | $21.8M | 56/100 |
Where Shuttle Pharmaceuticals Holdings, Inc. Ranks
Frequently Asked Questions
Is Shuttle Pharmaceuticals Holdings, Inc. profitable?
No, Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reported a net loss of $11.7M in fiscal year 2025.
What is Shuttle Pharmaceuticals Holdings, Inc.'s EBITDA?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) had EBITDA of -$11.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Shuttle Pharmaceuticals Holdings, Inc.'s return on equity (ROE)?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has a return on equity of -519.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Shuttle Pharmaceuticals Holdings, Inc.'s operating cash flow?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) recorded an outflow of $9.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Shuttle Pharmaceuticals Holdings, Inc.'s total assets?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) had $10.5M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Shuttle Pharmaceuticals Holdings, Inc. spend on research and development?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) invested $4.1M in research and development during fiscal year 2025.
What is Shuttle Pharmaceuticals Holdings, Inc.'s current ratio?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) had a current ratio of 0.06 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Shuttle Pharmaceuticals Holdings, Inc.'s liabilities-to-equity ratio?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) had a liabilities-to-equity ratio of 3.65 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Shuttle Pharmaceuticals Holdings, Inc.'s return on assets (ROA)?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) had a return on assets of -111.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Shuttle Pharmaceuticals Holdings, Inc.'s P/E ratio?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $24.0M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Shuttle Pharmaceuticals Holdings, Inc.'s price-to-sales ratio?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $24.0M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Shuttle Pharmaceuticals Holdings, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Shuttle Pharmaceuticals Holdings, Inc. (SHPH) held $334K in cash, cash equivalents and investments, and reported an operating cash outflow of $9.5M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Shuttle Pharmaceuticals Holdings, Inc.'s Piotroski F-Score?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Shuttle Pharmaceuticals Holdings, Inc.'s earnings high quality?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reported a net loss of $11.7M while operations used $9.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.